newsfilter
← Latest News
Business Wire·

Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results

Company Plans to Commence New FX-322 Phase 2 Study in Q4 2021 in a Refined Population of Individuals with Sensorineural Hearing Loss (SNHL) Will Host R&D Event on November 9th to Provide Detailed Insights into FX-322 Clinical Data, Plans for Continue